Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial

Journal of Clinical Oncology

Volumn 19, Issue 1, 2001, Pages 127-136

  Hayman, J A ^a   Martel, M K ^a   Ten Haken, R K ^a   Normolle, D P ^a   Todd III, R F ^a   Littles, J F ^a   Sullivan, M A ^a   Possert, P W ^a   Turrisi, A T ^a   Lichter, A S ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION PNEUMONIA; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0035154254     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.1.127     Document Type: Article

References (45)

1. Improved survival in stage III non-small-cell lung cancer: Seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial
2. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: First analysis of a randomized trial in 353 patients
3. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer
4. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
5. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis
6. Impact of tumor control on survival in carcinoma of the lung treated with irradiation
7. Optimization of radical radiotherapy with beam's eye view techniques for non-small cell lung cancer
8. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer
9. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: Possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma - Report of Radiation Therapy Oncology Group 83-11
10. Dose escalation for non-small cell lung cancer using conformal radiation therapy
11. eff and iso-NTCP in the implementation of dose escalation protocols
12. Complication probability as assessed from dose volume histograms
13. Optimization of radiation therapy III: A method of assessing complication probabilities from dose volume histograms
14. Tolerance of normal tissue to therapeutic irradiation
15. Fitting of normal tissue tolerance data to an analytic function
16. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis
17. Histogram reduction method for calculating complication probabilities for 3D treatment planning evaluations
18. Analysis of clinical complication data for radiation hepatitis using a parallel architecture model
19. The delay before onset of accelerated tumour cell repopulation during radiotherapy: A direct maximum-likelihood analysis of a collection of worldwide tumour-control data
20. Pulmonary effects of radiation therapy
21. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial
22. Induction chemoradiation therapy followed by surgery in stage IIIA non-small carcinoma of the lung (NSCLC): Long term results of Cancer and Leukemia Group B protocol 8634
23. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: Mature results of Southwest Oncology Group phase II study 8805
24. Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer
25. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer
26. The treatment of stage III nonsmall cell lung cancer using high dose conformal radiotherapy
27. Radiation therapy in the management of medically inoperable carcinoma of the lung: Results and implications for future treatment strategies
28. Radiotherapy as an alternative to surgery in elderly patients with resectable lung cancer
29. The influence of tumor size and pre-treatment staging on outcome following radiation therapy alone for stage I non-small cell lung cancer
30. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: The Duke experience
31. Prospects for dose escalation in stage III non-small cell lung cancer using "involved field" radiotherapy with or without gating: A planning study. World Congress on Medical Physics and Biomedical Engineering, Nice, France, 1997
32. Three-dimensional radiation treatment planning study for patients with carcinoma of the lung
33. Analysis of the influence of elective nodal irradiation on postirradiation pulmonary function
34. Incidental dose to clinically negative nodes from conformal treatment fields for nonsmall cell lung cancer
35. Elective nodal irradiation in the treatment of non-small cell lung cancer with three-dimensional conformal radiation therapy
36. Measurement of patient setup errors using port films and a computer-aided graphical alignment tool
37. What margins should be added to the clinical target volume in radiotherapy treatment planning for lung cancer?
38. Analysis of movement of intrathoracic neoplasms using ultrafast computerized tomography
39. Respiration gated radiotherapy treatment: A technical study
40. The use of active breathing control (ABC) to reduce margin for breathing motion
41. Deep inspiration breath-hold technique for lung tumors: The potential value of target immobilization and reduced lung density in dose escalation
42. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: Challenges and prospects
43. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis
44. The contribution of 18-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer
45. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer